Abstract
Neurons require intracellular transport of essential components for function and viability and defects in transport has been implicated in many neurodegenerative diseases including Alzheimer’s disease (AD). One possible mechanism by which transport defects could occur is by improper regulation of molecular motors. Previous work showed that reduction of presenilin (PS) or glycogen synthase kinase 3 beta (GSK3β) stimulated amyloid precursor protein vesicle motility. Excess GSK3β caused transport defects and increased motor binding to membranes, while reduction of PS decreased active GSK3β and motor binding to membranes. Here, we report that functional PS and the catalytic loop region of PS is essential for the rescue of GSK3β-mediated axonal transport defects. Disruption of PS loop (PSΔE9) or expression of the non-functional PS variant, PSD447A, failed to rescue axonal blockages in vivo. Further, active GSK3β associated with and phosphorylated kinesin-1 in vitro. Our observations together with previous work that showed that the loop region of PS interacts with GSK3β propose a scaffolding mechanism for PS in which the loop region sequesters GSK3β away from motors for the proper regulation of motor function. These findings are important to uncouple the complex regulatory mechanisms that likely exist for motor activity during axonal transport in vivo.
Introduction
Presenilin (PS) is an evolutionarily conserved, multipass transmembrane (TM) protein (1) with a single large hydrophilic loop between TM domains 6 and 7 (2,3). PS is essential for development as knockout of PS in mice (4–6) and flies (7,8) are lethal. PS has been implicated in multiple physiological roles, such as calcium homeostasis (9), membrane trafficking (10) and cell–cell adhesion (11). In mammals, PS exists as two homologs (PS1 and PS2) which share 67% similarity and are redundant in their functions (12–15) but only a single PS homolog is present in Drosophila (16,17). However, in Drosophila, PS undergoes alternative splicing (17), generating two isoforms (PS+14 and PS−14) that differ with respect to a 14 amino acid insertion in the hydrophilic loop domain, but show functional similarity (18).
PS undergoes endoproteolytic processing within the exon-9 region of the hydrophilic loop resulting in N- and C-terminal fragments (19). Two conserved aspartate residues, Asp 257 in TM6 and Asp 385 in TM7, are critical for endoproteolysis of PS (13). Endoproteolysis is essential for PS’s ‘presenilase’ function, defined by the ability to act as an autoactivated intramembranous aspartyl protease (13,20), identified by the lack of presenilase inhibition by several potent γ-secretase inhibitors (21); and for its γ-secretase function, identified by intramembrane cleavage of the TM protein amyloid precursor protein (APP) (22,23). Further, autoproteolysis of PS was proposed to cause conformational changes to the loop domains of PS (24). Modeling analysis has shown that conformational changes critical for the maturation of PS activity within the exon 9 loop directly controls access to a channel-like interior and to the catalytic site (25,26), demonstrating the complexity of PS function.
Over 150 mutations in PS contribute to early-onset familial Alzheimer’s disease (FAD) but it is unclear whether these PS mutations contribute to a gain of function (6,27) or a loss of function disease mechanism (28,29). The FAD PSΔE9 mutation results in the deletion of exon 9, encoding part of the hydrophilic loop (30). Although this mutation fails to undergo endoproteolytic cleavage in mice (31) and in cells (19), normal γ-secretase activity was seen as APP and Notch were cleaved in mammalian cells (13,19). However, γ-secretase activity was reduced in isogenic human PSΔE9 patient stem cells (27). FAD mutations PS D257A and PS D385A carry amino acid substitutions at the two conserved aspartate residues within TM6 and TM7, and mimic non-functional PS or a PS-null state with no endoproteolysis (13) with diminished γ-secretase cleavage of APP in mammalian cells (13,32). A similar effect was observed when an aspartate residue in PS2 was mutated (D366A) (14). γ-secretase activity was completely abolished when aspartate residues in both PS1 and PS2 were mutated (33). Additionally, PS D257A and PS D385A mutations prevent Notch cleavage (34), however, the trafficking of Notch to the plasma membrane was unaffected (32,35,36). In addition to the γ-secretase function, studies have shown that PS also has a scaffolding role to facilitate β-catenin phosphorylation by protein kinase A (PKA) and glycogen synthase kinase 3 beta (GSK3β) (37) and for its turnover (38–40). In this context, amino acids 250–298 interacts with GSK3β (41,42) and amino acids 299–427 binds β-catenin (37), bringing GSK3β to β-catenin for its phosphorylation (43). Deletion of the loop region, including the GSK3β binding site (41) in the PSΔE9 mutant showed reduced affinity for GSK3β and slowed the rate of β-catenin turnover (39). Work has also shown that phosphorylation of serine 353 and 357 of PS by GSK3β induces a structural change in the hydrophilic loop of PS, which reduced the interaction of β-catenin and decreased its turnover (43). Although it is unclear how a scaffolding function for PS contributes to AD, the FAD PSΔE9 mutant showed increased Aβ production (23,44).
Studies have shown that PS has a role during axonal transport. PS moves bidirectionally within both peripheral nervous system (PNS) (45,46) and central nervous system axons (47) and was proposed to be present with APP containing axonal vesicles (48). Consistent with this, genetic reduction of PS in Drosophila larval nerves stimulated both the anterograde and retrograde velocities of APP vesicles but not synaptotagmin (SYNT) vesicles (49). Strikingly, a similar phenotype was observed with genetic reduction of GSK3β in Drosophila (50). Although biochemical associations between PS and GSK3β have been observed (39,41), we previously showed a functional interaction between PS and GSK3β in the context of axonal transport (51). Although homozygous PS or GSK3β loss of function mutants are lethal, larvae heterozygous for both PS and GSK3β show a paralytic crawling phenotype and do not eclose to adults (51). These larvae also contained axonal blockages at levels comparable to homozygous loss of function motor protein mutants (52). Intriguingly, heterozygous PS mutants showed decreased active GSK3β on membranes together with decreased kinesin and dynein binding to membranes, similar to heterozygous GSK3β mutants. Together, these observations suggest that PS and GSK3β are functionally coupled during axonal transport. Since in vitro work in cells has suggested that GSK3β can phosphorylate kinesin light chain (KLC), releasing kinesin from vesicles (53), perhaps PS is involved in controlling GSK3β-mediated roles on motor proteins during axonal transport. Since the hydrophilic loop region of PS binds GSK3β (41) perhaps PS loop is essential for these GSK3β-mediated roles on axonal transport. Alternatively, since PS was shown to be an unprimed substrate of GSK3β (54) and that GSK3β activity modified the localization and function of PS (55), perhaps GSK3β is involved in PS-mediated roles during axonal transport. Here, we test these predictions using Drosophila genetics, biochemical analysis and in vivo imaging. Our observations show that an intact loop region and functional PS is essential for proper axonal transport. Our results propose a model in which the hydrophilic PS loop region sequesters GSK3β away from motors likely for the proper regulation of motor function during axonal transport in vivo.
Results
Functional PS is required to rescue GSK3β-mediated axonal transport defects
One prediction of the hypothesis that PS and GSK3β are functionally coupled during axonal transport is that functional PS is required for GSK3β-mediated roles during axonal transport. Previously, we showed that expression of the Drosophila homolog of GSK3β, Shaggy (SGG), in all neurons using the APPL-GAL4 driver caused axonal blockages compared with wild-type (WT) (51) (Fig. 1A–C). Larval segmental nerves from larvae expressing SGGWT contained accumulations of the synaptic vesicle protein cysteine string protein (CSP), similar to what was observed in larvae containing loss of function mutations of genes encoding motor proteins (56–58). These accumulations are called axonal blockages and are observed both in fixed (51,52,56,58–62) or live larval segmental nerves (52,60,61,63–65) and has been used to successfully identify novel genes involved in axonal transport (58,61,62,64,66). Under electron microscopy, many types of identifiable axonal cargo (mitochondria, dense core vesicles) are observed within these axonal blockages (49,57,58). In contrast to larvae expressing GSK3β/SGG, expression of Drosophila PS (PS+14 or PS−14) in all neurons did not show axonal blockages but showed smooth CSP staining, similar to what is observed in segmental nerves from WT larvae (Fig. 1A and D, Supplementary Material, Fig. S1C). To test that functional PS is required for GSK3β-mediated roles, we generated larvae expressing both SGGWT and PS. As a control, we also generated larvae expressing both SGGWT and GFP (UAS-EGFP). Strikingly, we observed that larvae expressing both SGGWT and PS+14 showed smooth CSP stained segmental nerves (Fig. 1E). Note that larvae expressing SGGWT and GFP show axonal blockages at similar levels to larvae expressing SGGWT alone (Fig. 1J), indicating that the rescue we observe is specific and is not due to competing events for two transgenes within one organism. Excess PS also rescued axonal blockages seen in larvae expressing SGGACTIVE alone. Larvae expressing both SGGACTIVE and PS+14 or PS−14, also contained smooth CSP stained segmental nerves (Fig. 1F, Supplementary Material, Fig. S1). Quantification analysis of the average number of axonal blockages per larvae indicated that the extent of blockages seen in larvae expressing SGGWT (P < 0.05) or SGGACTIVE (P < 0.05) alone was significantly rescued with the expression of PS (Fig. 1H and I, Supplementary Material, Fig. S1I). These observations are in contrast to our previous work that showed that larvae expressing GSK3β/SGG in the context of 50% reduction of PS enhanced axonal blockages (51). Therefore, rescue of GSK3β-mediated axonal blocks could result by a stoichiometric requirement of functional PS.
PS undergoes endoproteolytic cleavage generating N- and C-terminal fragments (NTF and CTF) (19), which is essential for PS function (67). To further test that functional PS is required for GSK3β-mediated axonal transport, we used the FAD-linked Drosophila PS mutant PSD447A, which mimics the D385A amino acid substitution at the conserved aspartate residue within TM7 and encodes a non-functional form of PS that shows defective endoproteolysis and γ-secretase activity (13). Intriguingly, larvae expressing PSD447A in all neurons showed CSP-positive axonal accumulations within their segmental nerves, in contrast to larvae expressing PS (Fig. 1G). Larvae expressing PSD447A in the context of excess SGGWT also showed axonal blockages (Fig. 1H). Quantification of the average number of axonal blockages per larvae indicate that the extent of blockages in larvae expressing PSD447A with SGGWT was significantly increased compared with larvae expressing PSD447A alone (P < 0.05) or SGGWT (P < 0.005) alone (Fig. 1K). A similar increase in axonal blockages was also seen in larvae expressing PSD447A with SGGACTIVE (P < 0.005, Fig. 1I). These observations are consistent with our previous work that showed that larvae expressing SGG in the context of 50% reduction of PS enhanced GSK3β-mediated axonal blockages (51). Therefore, functional PS is required to rescue GSK3β-mediated axonal transport defects.
An intact PS loop is required to rescue GSK3β-mediated axonal transport defects
Studies have proposed that the hydrophilic loop region of PS binds GSK3β to mediate GSK3β dependent phosphorylation of β-catenin in the wnt-β-catenin signaling pathway (38–40). Similarly, perhaps the PS hydrophilic loop could also modulate GSK3β-mediated axonal transport defects. To test this possibility, we examined larvae expressing human PS loop or Drosophila PS loop in all neurons using the APPL-GAL4 driver. The UAS-human PS loop line expresses amino acids 263–407 of human PS which includes TM7 (68). The UAS-Drosophila PS (+14) loop line expresses the hydrophilic loop and TM7 following the loop (8). We found that similar to larvae expressing full-length PS, larvae expressing human PS loop (hPSloop) or Drosophila PS loop (dPSloop) alone showed smooth CSP stained segmental nerves which was comparable to WT larval nerves (Fig. 2D, Supplementary Material, Fig. S2). Strikingly, larvae expressing both SGGWT and hPSloop or dPSloop showed smooth CSP staining with no axonal blockages, in contrast to larvae expressing SGGWT alone (Fig. 2E, Supplementary Material, Fig. S2). Expression of hPSloop or dPSloop also rescued axonal blockages seen in larvae expressing SGGACTIVE (Fig. 2F, Supplementary Material, Fig. S2).
To further test that the loop region of PS is required for the modulation of GSK3β-mediated axonal transport defects, we examined larvae expressing the FAD mutant PSΔE9. In PSΔE9, residues 291–319, the part of the loop region encoded by exon 9 is deleted (30). This mutation fails to undergo endoproteolytic cleavage (19,31), but normal γ-secretase activity was seen (13). In contrast to larvae expressing dPSloop or hPSloop, larvae expressing PSΔE9 contained axonal blockages that stained with CSP (Fig. 2G). Larvae expressing both PSΔE9 and SGGWT also contained axonal blockages (Fig. 2H). Similarly, larvae expressing both PSΔE9 and SGGACTIVE also showed axonal blockages (Fig. 2I). Quantification analysis revealed that the extent of blockages in larvae expressing both PSΔE9 and SGGACTIVE was significantly increased compared with larvae expressing SGGACTIVE (P < 0.005) alone or PSΔE9 (P < 0.05) alone. The increase in axonal blockages seen in larvae expressing both PSΔE9 and SGGWT was significant compared with SGGWT (P < 0.05) alone but not to PSΔE9 alone (P > 0.05). Although these observations indicate that the functional loop region of PS is required to rescue GSK3β-mediated axonal blockages, perhaps an intact PS loop may also be required to modulate GSK3β activity or motor binding to membranes. Indeed, exon 9 encompasses the GSK3β binding site on PS (41,42) and we previously showed that excess motor binding to membranes was correlated to axonal transport defects (51).
Functional PS and an intact PS loop are needed for proper kinesin and dynein binding to membranes
We previously showed that 50% reduction of PS decreased membrane binding of kinesin and dynein (51). The binding of active GSK3β to membranes was also decreased with 50% genetic reduction of PS (51). Similarly, 50% reduction of GSK3β/SGG also showed decreased membrane binding of active GSK3β and both kinesin and dynein (51). These studies propose that both PS and GSK3β are involved in mediating motor protein binding to membranes. In the wnt-β-catenin signaling pathway, binding of GSK3β to the hydrophilic loop of PS is proposed to mediate GSK3β dependent β-catenin phosphorylation (38–40). Therefore, the simplest prediction of how excess PS rescues GSK3β-mediated transport defects could be by binding GSK3β to the loop and titrating excess active GSK3β away from motors. This would prevent GSK3β from acting on motors, resulting in the decrease of motor binding to membranes. To test this prediction, we used biochemical analysis to fractionate membranes from adult fly brains expressing PS loop alone and adult fly brains expressing PSΔE9 alone. We found that the level of kinesin-1 was significantly increased in the membrane fraction from brains expressing PSΔE9 (P < 0.005, Student’s t-test and Tukey’s Honest Significant Difference (HSD) test and Bonferroni’s test), while no changes were seen in brains expressing PS loop (Fig. 3B). The level of active GSK3β bound to membranes was also increased in brains expressing PSΔE9 but this increase was not significant. Therefore, an intact PS loop is required for the proper binding of kinesin and perhaps for the binding of active GSK3β to membranes.
To further test that functional PS also contributes to motor binding to membranes, we fractionated membranes from fly brains expressing PS+14 and brains expressing PSD447A, the non-functional form of PS that is defective in endoproteolysis and γ-secretase activity. We found that the level of both kinesin and dynein was increased in the membrane fraction from brains expressing PSD447A in contrast to brains expressing PS+14 alone (Fig. 4B, for kinesin-1 P < 0.05, Student’s t-test, Tukey’s HSD test and Bonferroni’s test, for dynein P < 0.005, Student’s t-test, Tukey’s HSD test and Bonferroni’s test). Interestingly, the level of active GSK3β was also increased in the membranes from brains expressing PSD447A in contrast to brains expressing PS+14 alone (P < 0.005, Student’s t-test, Tukey’s HSD test and Bonferroni’s test). Therefore, a functional PS is essential for proper motor protein binding to membranes and for the membrane binding of active GSK3β.
Kinesin associates with active GSK3β and is phosphorylated in vitro
Previous studies in cells suggested that binding of kinesin-1 to membranes depends on the phosphorylation state of KLC, and that GSK3β-mediated phosphorylation of KLC releases kinesin from vesicles (53). Other work suggested that phosphorylation of kinesin heavy chain (KHC) can also induce membrane association (69). Therefore, one potential role for a functional PS and/or an intact loop region of PS is to bring active GSK3β to motors for their phosphorylation, similar to the mechanism proposed for β-catenin (38–40). One prediction of this proposal is that active GSK3β and motors should associate. To test this possibility, using immunoprecipitation we isolated KHC from adult fly brains using an antibody against KHC. Western blot analysis showed that active GSK3β coimmunoprecipitated (co-IP) with KHC, indicating that KHC and active GSK3β can associate in vitro (Fig. 5A). Interestingly, our observations complement previous work that showed that GSK3β co-IPed with dynein intermediate chain (DIC) (70) and KLC (53), indicating that motors and GSK3β can exist as a complex.
A second prediction is that active GSK3β should phosphorylate motors. Indeed, early work showed that both KHC and KLC are endogenously phosphorylated (69,71), however, the identity of the kinase(s) responsible is not known. Drosophila KHC has two putative GSK3β phosphorylation sequences, one within the kinesin motor domain and the other within the stalk. To test whether Drosophila KHC is directly phosphorylated by GSK3β, we used an in vitro kinase assay. KHC was first isolated by immunoprecipitation from adult fly brain extracts and this fraction was incubated with recombinant glutathione S-transferase (GST) tagged active GSK3β in the presence of γ-32P-ATP. Strikingly, the autorad showed a γ-32P positive band at ∼110 kDa corresponding to KHC (Fig. 5B). We also note that a γ-32P positive band was seen at ∼74 kDa which we predict is the autophosphorylation of GST-GSK-3β that was added to the reaction. Note that these bands disappear when the reaction was incubated with the GSK3β specific inhibitor CT99021, although the Coomassie gel still shows proteins. These observations are consistent with previous work using mouse brains that showed that dynein light chain, intermediate chain and light intermediate chains were all phosphorylated by GSK3β in vitro (70). Studies using rat brains indicated that KLC but not KHC was phosphorylated by GSK3β (53), however, here we demonstrate that KHC can also be phosphorylated by GSK3β.
GSK-3β influences the subcellular localization of PS within larval nerves
Previous studies showed that PS is an unprimed substrate of GSK3β (54) and that GSK3β activity modifies the localization and the function of PS (55). Typically, PS is localized to the endoplasmic reticulum and Golgi membranes (72). However, endogenous PS also localizes at the plasma membrane as an active molecule (73). In neurons, PS binds to β-catenin and N-(and E-) cadherin through the hydrophilic loop region at the synapse (11). Biochemical analysis showed that PS is also present in endocytic vesicles (32) and is part of APP-containing vesicles in mouse segmental neurons (48). Since we previously found that PS (49), like GSK3β (50) can control kinesin and dynein function during the axonal movement of APP in vivo, an alternative prediction of the hypothesis that PS and GSK3β are functionally coupled during axonal transport is that GSK3β influences the function of PS during axonal transport. To test this prediction, we evaluated the neuronal localization pattern of PS by generating larvae expressing GFP-tagged Drosophila PS in all neurons using the APPL-GAL4 driver, since a robust Drosophila PS antibody was unavailable. PS was present within the cell bodies in the larval brain and within larval nerves (Fig. 6A and B). Active GSK3β was also observed in larval brains (cell bodies, Supplementary Material, Fig. S4A), larval segmental nerves (Supplementary Material, Fig. S4B) as well as in the neuromuscular junctions (NMJs, Supplementary Material, Fig. S4C). Similar to larvae expressing PS+14 or PS−14, the GFP-PS expressing larvae also did not show axonal blockages (Fig. 6D, Supplementary Material, Fig. S1C).
To test how GSK3β influences the neuronal localization of PS, we generated larvae expressing both SGGWT and GFP-PS. Axonal blockages mediated by excess SGGWT were also rescued by expressing GFP-PS similar to Figure 1E, indicating that the N-terminal GFP-tagged PS was functional. Intriguingly, in contrast to larvae expressing GFP-PS alone, larvae expressing both SGGWT and GFP-PS showed increased GFP-PS within cell bodies in the larval brain and very faint GFP-PS in larval nerves (Fig. 6E and F). Quantification analysis of four cell bodies each from eight larvae (total of 32) revealed a significant increase in the level of GFP-PS present in the cell bodies in larvae expressing SGGWT and GFP-PS in contrast to larvae expressing GFP-PS alone (P < 0.005). In addition, a significant decrease was seen in the level of GFP-PS in these larval nerves compared with larvae expressing GFP-PS alone (P < 0.005). A similar phenotype was also seen in larvae expressing SGGACTIVE with GFP-PS (Fig. 6G and H). Since excess active GSK3β restricted GFP-PS to the cell bodies decreasing GFP-PS from the larval nerves, we predict that loss of GSK3β should disrupt this localization. To test this possibility, we generated larvae expressing SGGDN and GFP-PS, since loss of function mutations of SGG result in embryonic lethality (74). Larvae expressing SGGDN alone showed axonal blockages at levels greater than what was observed for larvae expressing SGGWT or SGGACTIVE (Supplementary Material, Fig. S3B). In addition, western blot analysis of total proteins from brains expressing SGGDN showed that the level of active GSK3β was significantly decreased (Supplementary Material, Fig. S3D and E, P < 0.05, Student’s t-test, Tukey’s HSD test and Bonferroni’s test) compared with WT, indicating that SGGDN likely functions as a hypomorph, consistent with what was previously shown (74). In contrast to larvae expressing GFP-PS and SGGWT, larvae expressing both GFP-PS and SGGDN showed increased GFP-PS within larval nerves (Fig. 6I and J). However, the level of GFP-PS in the cell bodies located in the larval brain was comparable to what was observed in larvae expressing GFP-PS alone (Fig. 6I and J). Taken together, our observations indicate that active GSK3β influences the subcellular localization of PS within larval nerves. Therefore, perhaps the GSK3β-mediated axonal blockages we observe in larval nerves (Figs 1–4) could be due to the restriction of PS to cell bodies. Although PS has two consensus phosphorylation sequences in its hydrophilic loop region (54,75), whether GSK3β-mediated phosphorylation is involved in the localization of PS is unknown.
Discussion
We have identified a critical physiological role for the hydrophilic loop region of PS during GSK3β-mediated axonal transport using genetics, biochemistry and in vivo imaging in Drosophila. Our observations done in an intact organism allow us to propose a scaffolding mechanism for PS in regulating GSK3β-mediated functions on molecular motors during their motility in vivo. In contrast to the scaffolding role of PS proposed in the wnt-β-catenin signaling pathway, we report that the hydrophilic PS loop region likely sequesters GSK3β away from motors to rescue excess GSK3β-mediated axonal blockages. These findings have important implications for our understanding of the complex functions of PS and for the complicated regulatory mechanisms that must control motor protein activity during axonal transport in vivo.
A scaffolding role for PS during GSK3β-mediated axonal transport
In addition to the proteolysis function of PS, a scaffolding role for PS was demonstrated during β-catenin dependent signaling. Early work showed that β-catenin directly binds PS via the large hydrophilic loop domain (40,76,77). However, whether this interaction stabilized β-catenin or enhanced the degradation of β-catenin was unclear. Although overexpression of WT PS in COS7 cells reduced cytoplasmic β-catenin, FAD PS mutants showed no effect (40). In contrast, overexpression of PS and β-catenin in HEK293 cells enhanced β-catenin stability, and this ability was decreased in FAD PS mutants (38). GSK3β bound to the N-terminal fragment of PS and β-catenin bound to the C-terminal fragment of PS facilitated the turnover of β-catenin (39). Further, these associations were decreased in FAD PSΔE9 indicating that the loop region plays an important role. Studies also proposed that PS was key in a stepwise phosphorylation mechanism of β-catenin, mediated first by PKA and then by GSK3β which ensures proper ubiquitination and degradation of β-catenin (37). Other work showed that phosphorylation of the serine residues in the hydrophilic loop region of PS by GSK3β induces a structural change in PS that reduces GSK3β interaction with β-catenin, decreasing β-catenin phosphorylation and ubiquination, stabilizing β-catenin (43). Although the scaffolding mechanism for PS has thus far been detailed only in the context of β-catenin signaling in in vitro studies, it is unclear whether such a mechanism exists in vivo and whether it is essential in the context of PS-mediated functions; to bring substrates for γ-secretase cleavage.
Our results here together with previous in vivo analysis in Drosophila indicate that the roles of PS (49) and GSK3β (50) are tightly coupled during axonal transport (51), enabling us to propose a scaffolding mechanism for PS in the regulation of GSK3β-mediated functions on motor proteins. Specifically, we propose a model in which the hydrophilic loop of PS is involved in facilitating GSK-3β-mediated functions on motor proteins. In this context at least two possibilities could exist. One possibility is that similar to the scaffolding role of PS in the wnt-β-catenin pathway, PS via its loop region brings GSK3β to motor proteins. An alternative possibility is that PS via its loop region sequesters GSK3β away from motors. Our observations favor a sequestering mechanism for the PS loop in titrating GSK3β away from motors (Supplementary Material, Fig. S5). Although we were unable to evaluate direct interactions between Drosophila PS and GSK3β due to the lack of robust antibodies, other work done in human, mice and monkey cells showed that GSK3β can bind to residues 250–298 of the PS loop (41) and that residues 263–298 of the PS loop is required for minimum binding of GSK3β (42). The PSΔE9 mutant lacking residues 219–391 showed decreased affinity for GSK3β (39). Additionally, KHC (Fig. 5A), KLC (53) or DIC (70) co-IP with GSK3β, indicating that motors and GSK3β can exist as a complex, similar to PS and GSK3β (39,41). Taken together, we propose that excess Drosophila PS loop or human PS loop rescues axonal blockages mediated by excess SGGWT or SGGACTIVE (Fig. 2E and F, Supplementary Material, Fig. S1F and H) by binding excess GSK3β to the PS loop and titrating GSK3β away from motors (Supplementary Material, Fig. S5). Disruption of PS loop fails to titrate excess GSK3β away from motors enhancing GSK3β-mediated axonal blockages (Fig. 2H and I). However, in contrast to the wnt-β-catenin signaling pathway, our model predicts that PS-GSK3β and GSK3β-motor associations are independent, and that motors are unlikely to be in a PS-GSK3β complex (Supplementary Material, Fig. S5), as we previously observed that PS did not show obvious genetic interactions with kinesin-1 or dynein in the context of axonal blockages (49), unlike GSK3β and motors (50,51). Further, expression of full-length PS or PS loop had no effect on axonal transport (Figs 1D and 2D, Supplementary Material, Fig. S1C and E). Although further study is needed, whether excess PS-GSK3β are ‘marked’ for degradation however is unknown.
Our model is also consistent with the prediction that functional PS is also essential for the scaffolding mechanism of PS in GSK3β-mediated regulation of motor proteins during axonal transport. Expression of non-functional PS, PSD447A, that mimic a PS-null state with no endoproteolysis and γ-secretase activity also failed to rescue axonal blockages induced by excess SGGWT or SGGACTIVE (Fig. 1H and I), but instead, enhanced blockages. These results are consistent with our previous work that showed that 50% reduction of PS (using the loss of function Drosophila PS mutant) in the context of excess SGGWT or SGGACTIVE enhanced axonal blockages (51). However, unlike 50% reduction of PS, which showed decreased membrane binding of GSK3β (51), excess non-functional PS showed increased membrane binding of GSK3β, indicating that the non-functional PS, PSD447A does not fully mimic a PS-null state. One prediction is that PSD447A acts as a dominant negative in controlling GSK3β binding to membranes. Further, the PS and GSK3β association could be altered in PSD447A. Although the binding efficiency of GSK3β to PSD447A is unknown, GSK3β binding to the FAD mutant M146L was reduced (39). A second prediction is that structural modifications of the PS protein under physiological conditions could contribute to the complexity of PS functions on GSK3β during axonal transport in vivo. Indeed, endoproteolysis of PS is thought to cause conformational changes to the loop domains of PS (24). Phosphorylation of the PS loop region by GSK3β has also been proposed to cause structural changes that reduced interactions with β-catenin (43). Further, phosphorylation of PS at S367 in the loop causes a pathogenic ‘closed’ conformation (78), which was observed during both normal aging and in sporadic AD brains (79). Structural analysis and modeling studies showed that conformational modifications within the loop could directly control access to the channel-like interior and the catalytic site by a ‘gate-plug’ mechanism (25,26). Therefore, an aberrant conformational structure of the FAD PSD447A mutant which lacks both endoproteolysis and γ-secretase activities could be responsible for the dominant negative behaviors we observe.
GSK3β-mediated phosphorylation of motor proteins and PS during axonal transport
Our scaffolding mechanism for GSK3β-mediated regulation of axonal transport predicts that GSK3β and motors must associate (Supplementary Material, Fig. S5) perhaps for phosphorylation. Indeed, we found that KHC and active GSK3β are directly associated in co-IP analysis using fly brains (Fig. 5A). Work in mice and rats showed that GSK3β and DIC (70) or KLC (53) associate in co-IP analysis. However, whether active GSK3β also associates with DIC and KLC is unclear. Together, these studies indicate that motors and GSK3β can exist as a complex. A second prediction of our scaffolding model is that GSK3β should directly phosphorylate motor proteins. Indeed, we found that KHC isolated from fly brains was phosphorylated by active GSK3β in an in vitro kinase assay (Fig. 5B). Phosphorylation of KHC and autophosphorylation of GSK3β was inhibited by the GSK3β specific inhibitor CT99021 (Fig. 5C). Further, dynein light chain, intermediate chain and light intermediate chains were all shown to be phosphorylated by GSK3β in vitro in mouse brains (70). In rat brain extracts, KLC, but not KHC was shown to be phosphorylated by GSK3β (53). Perhaps the discrepancy in GSK3β-mediated phosphorylation of KHC in flies versus mice could be due to the fact that flies only have one KHC gene which contains putative GSK3β phosphorylation consensus sequences (51), while mammals have three KHC genes (KIF5A, B, C) with diverse expression patterns in different tissues/cells (80–83). KIF5A and KIF5C are expressed in neuronal tissues while KIF5B is ubiquitous (83). Intriguingly, sequence analysis shows that KIF5A and KIF5B contain putative GSK3β phosphorylation consensus sequences, while KIF5C does not. Additionally, since mammalian KHC and KLC genes also have sites for 5’ adenosine monophosphate-activated protein kinase (AMPK) phosphorylation (84) and sites for other kinases (85,86), perhaps specific kinases function to regulate motor subunits or to dictate functional specificity during axonal transport.
Phosphorylation of motors by GSK3β could mediate motor protein attachment to membranes, motor detachment from membranes or motor activity during axonal transport. It is thought that kinesin-1 motors adopt a folded compact conformation which is inactive or an extended, linear conformation which is active (87). In vitro experiments using GST-tagged kinesin showed that kinesin-1 motors on purified membranes were inactive, while attached to cargo (71,88). However, in other work, phosphorylation was shown to play a role in relieving the autoinhibition of two mitotic kinases (89). Although the mechanisms of kinesin-1 phosphorylation in the context of axonal transport are still unknown, several observations from cells, mice and flies hint at an important role for GSK3β-mediated phosphorylation. Increased GSK3β activity increased the levels of KLC phosphorylation leading to a reduction in membrane bound kinesin-1, disrupting anterograde transport in squid axoplasm (53,90). However, in other studies KHC phosphorylation induced membrane associations in mammalian cells (69). In another study kinesin motor activity, not membrane binding was proposed to be regulated by phosphorylation (71). Previously, we showed that genetic reduction of endogenous GSK3β in flies decreased motor binding to membranes, while excess of active GSK3β increased motor binding to membranes (51). Our observations here indicate that motor binding to membranes is coupled to active GSK3β (Figs 3 and 4), that active GSK3β restricts the localization of PS to cell bodies, preventing its function in the axon (Fig. 6), and that excess motors on membranes can cause axonal blockages. Therefore, while it is clear that GSK3β-mediated phosphorylation likely plays key roles in motor regulation, further investigations are needed to unravel the mechanistic details under physiological conditions.
In the scaffolding mechanism for β-catenin signaling, phosphorylation of PS at serine residues in the loop domain was proposed to negatively regulate the formation of the ternary complex between β-catenin, PS and GSK3β leading to decreased degradation and stabilization of β-catenin (43). Similarly, phosphorylation of PS at its loop domain could act as the switch that controls the GSK3β-mediated activities on motors. In our scaffolding model, a conformation change mediated by phosphorylation of PS loop could perhaps initiate GSK3β-PS interactions preventing associations between GSK3β and motors, thus regulating GSK3β-mediated effects on motors. Alternatively, GSK3β may dictate the subcellular localization of PS, restricting the functions of PS during axonal transport to a specific cellular compartment. Typically, PS has been shown to be localized mainly to the endoplasmic reticulum and Golgi membranes (72). However, endogenous PS was also found at the plasma membrane as an active molecule (73). In neurons, at synapses PS1 binds β-catenin and N-(and E-) cadherin through its hydrophilic loop (11). Uemura et al. (55), showed that GSK3β-mediated phosphorylation of PS1 reduced its binding to N-cadherin and downregulated the cell-surface expression of PS in CHO cells. PS was also proposed to be present within APP vesicles in axons (48). Our observations showed that excess active GSK3β increased PS localization to the cell bodies decreasing its entry into axons, while reduction of GSK3β increased PS localization to axons (Fig. 6I and J). Therefore, complex formation between PS and GSK3β could control the subcellular localization of PS thereby negatively mediating the subcellular compartment where GSK3β-mediated functions on motor proteins occur. Perhaps this is the reason for why reduction of PS and GSK3β only influenced the axonal motility of APP vesicles and not SYNT vesicles (49,50). Intriguingly, our previous observations showed that excess of PS or PS loop rescued APP-mediated axonal transport defects (91), indicating that APP is likely a key player in PS-GSK3β-mediated effects on axonal transport. Further studies are needed to test predictions of this proposal.
In summary, our observations suggest a scaffolding mechanism for PS in which the hydrophilic loop region sequesters GSK3β away from motors likely to control motor activities during axonal transport in vivo (Supplementary Material, Fig. S5). Although functional PS is also required, PS appears to act as the switch that negatively influences associations between GSK3β and motors during axonal transport. Further investigations in an in vivo system are needed to identify the mechanistic details of how GSK3β influences motor binding/release from membranes and/or motor activity. Thus our work highlights a key role for PS that is likely independent of its γ-secretase activity.
Materials and Methods
Drosophila genetics
Seven transgenic Drosophila PS lines UAS-PS+14, UAS-PS−14, UAS-hPSloopA8, UAS-dPSloop, UAS-PSΔE9, UAS-PSD447A and UAS-GFP-PS and three transgenic GSK3β lines, UAS-SGGB (SGGWT), UAS-SGGS9A (SGGACTIVE) and UAS-SGGA81T (SGGDN) were used. UAS-PS+14, UAS-PS−14 and UAS-dPSloop were obtained from Dr Mark E. Fortini and UAS-hPSloopA8 flies were obtained from Dr Norbert Perrimon. UAS-PSΔE9 and UAS-PSD447A and UAS-EGFP flies were obtained from Bloomington Stock Center. The UAS-GFP-PS line was generated by isolating Drosophila PS from cDNA clone LD23505 and cloning a 2072 bp insert into pUAST-NT-GFP (Richard Brusch). The pUAST-GFP-PS construct was injected into white eye Drosophila embryos and transformants were selected using eye color (GenetiVision). The pan neuronal driver APPL-GAL4 was used for neuronal expression of transgenic lines. For genetic interaction analysis, UAS-PS males were first crossed to APPL-GAL4; T(2:3), CyO, TM6B, Tb/Pin88K virgin females to obtain APPL-GAL4/y; UAS-PS/T(2:3), CyO, TM6B and Tb males. The chromosome carrying T(2:3), CyO, TM6B and Tb is referred to as B3 and carries the dominant markers, Hu, Tb and CyO. The larval Tb (tubby) marker is used to select larvae. The APPL-GAL4/y; UAS-PS/B3 males were crossed to virgin females that were UAS-SGGB(SGGWT), UAS-SGGS9A (SGGACTIVE) or UAS-SGGA81T (SGGDN), and non-tubby female larvae were dissected for immunohistochemistry. Sibling tubby larvae were evaluated as controls. Reciprocal crossings were also done to confirm observations. As a control, males that were APPL-GAL4/y; UAS-EGFP/B3 were also crossed to UAS-SGGB (SGGWT).
Larval preparations, immunohistochemistry and quantifications
Third instar larvae were dissected, fixed and segmental nerves were immunostained as previously described (92). Briefly, larvae were dissected in dissection buffer (2× stock containing 128 mM NaCl, 4 mM MgCl2, 2 mM KCl, 5 mM HEPES and 36 mM sucrose, pH 7.2). Dissected larvae were fixed in 8% paraformaldehyde, washed with PBT (phosphate buffered saline supplemented with 0.1% Tween-20) and incubated overnight with antibodies against CSP (1:10, Developmental Studies Hybridoma Bank) or pGSK3β (1:1000, Abcam). Larvae were incubated in secondary antibodies (Alexa anti-mouse 568, 1:100, Invitrogen) and mounted using Vectashield mounting medium (Vector Labs). Images of segmental nerves were collected using a Nikon Eclipse TE 2000U microscope using the 40× objective, and NMJs and cell bodies were imaged using the 100× objective (Nikon, Melville, NY, USA) microscope. Quantitative analysis on the extent of blockages was carried out by collecting six confocal optical images from larval neurons from the region directly below or posterior to the larval brain, where several segmental nerves are visible or come into focus through the optical series. For each genotype, five to seven animals were imaged, and nerves were analyzed over a length of 50 µm, using the threshold, density slice and particle analysis functions in NIH ImageJ software as previously described (52).
Membrane flotation and western blot analysis
Five milliliters of larval brains from each genotype (UAS-PS+14, UAS-PS−14, UAS-hPSloopA8, UAS-dPSloop, UAS-PSΔE9 and UAS-PSD447A) were collected and homogenized in acetate buffer (10 mM HEPES, pH 7.4, 100 mM K acetate, 150 mM sucrose, 5 mM EGTA, 3 mM Mg acetate, 1 mM DTT) with proteinase inhibitor (Roche) and phosphatase inhibitor (Invitrogen) (51,61). The homogenate was centrifuged at 1000g for 10 min and the debris were discarded. The resulting PNS was brought to 40% sucrose. This mixture was overlaid with cushions of 35 and 8% sucrose and the gradient was centrifuged at 50 000g for 1.5 h in a TLS55 rotor (Beckman Coulter, Fullerton, CA, USA). Vesicles, membranous organelles and membrane-associated proteins were found at the 35/8 interface, while heavier membranes and mitochondria were found in the pellet. Equal amounts of protein from the PNS, 35/8 interface, soluble and pellet fractions were analyzed by western blotting. Antibodies pY216 GSK3β monoclonal antibody (Abcam at 1:1000), GSK3β total polyclonal antibody (Cell Signaling at 1:1000), anti-KHC polyclonal antibody (Cytoskeleton at 1:1000), anti-DIC monoclonal antibody (Abcam at 1:1000), anti-Rab5 polyclonal antibody (Abcam 1:1000) and anti-tubulin monoclonal antibody (Invitrogen at 1:1000 dilution) were used. Immunoreactions were detected using the SuperSignal West Femto Maximum sensitivity substrate (Invitrogen) and imaged using QuantityOne (Bio-Rad). Quantification analysis was performed using Imagelab software. Relative intensities was calculated by dividing the intensity value for each sample by the intensity value of Rab5 and then normalized to WT, so that WT was 1. Statistical significance was calculated using two-sample two-sided Student’s t-test, Tukey’s HSD test and Bonferroni’s test, specially designed to compare each treatment with a control. Differences were considered significant at a significance level of 0.05, which means a 95% statistically significant correlation from three separate membranes from three independent experiments.
Fly head extract preparation and KHC Immunoprecipitation
For preparation of Drosophila head extracts, 8 ml of fly heads from WT flies were homogenized in acetate buffer as previously described (51,61). The lysate was centrifuged at 1000g for 10 min at 4°C. Concentrations of the extracts were determined using bicinchoninic acid (BCA) protein assay (Pierce). For IP, 2 mg of the fly head lysate was incubated overnight with 4 µg KHC antibody (Cytoskeleton) at 4°C. Protein A/G Magnetic Beads (Pierce) washed in wash buffer (Tris-buffered saline containing 0.05% Tween-20) was added to the mixture and incubated at room temperature for 1 h. Magnetic beads were then eluted in 100 µl low pH elution buffer (Pierce). The low pH was neutralized by adding 15 µl Tris pH 8.8. The concentration of the KHC pull down was determined by BCA assay. Western blot analysis was used to evaluate the extent and purity of the KHC immunoprecipitation as seen in Figure 5A.
In vitro GSK3β phosphorylation assay
Recombinant GST-GSK3β (SignalChem) was used for the in vitro kinase assay. Potential substrates (KHC IP) were incubated with 50 ng GSK3β and 1mCi/100 γ32P-ATP for 30 min at 37°C. The reaction was terminated using 4X sample buffer. Control reactions containing 3 µM of GSK3β inhibitor CT99021 (Selleck) were done to evaluate the specificity of the GSK3β phosphorylation assay. Proteins were separated by SDS-PAGE, the gel was dried and sealed in saran wrap and exposed to X-ray film overnight. After exposure, gels were stained with Coomassie brilliant blue to visualize proteins.
Statistical analysis
For immunofluorescence analysis of axonal blockages, statistical analysis was performed in Excel (Microsoft Corp.), using the two-sample two-sided Student’s t-test. Differences were considered significant at a significance level of 0.05, which means a 95% statistically significant correlation for 5–10 individual larvae from several independent crosses. For western blots, quantification analysis was performed using Image Lab software. Data obtained from Image Lab was analyzed in Excel (Microsoft Corp.) using two-sided Student’s t-test. Additionally, Bonferroni’s test and Tukey’s HSD test was performed in Minitab 18. Both of the methods are pair-wise multiple comparison procedures specifically designed to compare each treatment with a control (93,94). Differences were considered significant at a significance level of 0.05, which means a 95% statistically significant correlation from three separate membranes from three independent experiments.
Supplementary Material
Acknowledgements
The authors thanks the members of the Gunawardena Lab for their constructive discussions and insight. The authors also thank Drs Mark E Fortini and Norbert Perrimon for providing the transgenic PS fly lines. S.G. thanks Priyantha Karunaratne for constant support. This work is dedicated to the memory of Richard Brusch.
Conflict of Interest statement. None declared.
Funding
This work was supported in part by funds from NIH/NINDS (R03-NS084386 and R03-NS092024) and by a grant from the Office of the Vice President for Research and Economic Development (OVPRED) from SUNY at Buffalo to S.G. R.B. was supported in part by the Mark Diamond Research Fund from SUNY at Buffalo, Z.R. and C.N. were supported by fellowships from the Center for Undergraduate Research and Creative Activities (CURCA) from SUNY at Buffalo. C.N. was also supported by a fellowship by a Collegiate Science and Technology Entry Program (CSTEP) research fellowship from SUNY at Buffalo.
References
- 1. Laudon H., Hansson E.M., Melen K., Bergman A., Farmery M.R., Winblad B., Lendahl U., von Heijne G., Naslund J. (2005) A nine-transmembrane domain topology for presenilin 1. J. Biol. Chem., 280, 35352–35360. [DOI] [PubMed] [Google Scholar]
- 2. Sherrington R., Rogaev E.I., Liang Y., Rogaeva E.A., Levesque G., Ikeda M., Chi H., Lin C., Li G., Holman K. (1995) Cloning of a gene bearing missense mutations in early-onset familial Alzheimer’s disease. Nature, 375, 754–760. [DOI] [PubMed] [Google Scholar]
- 3. Doan A., Thinakaran G., Borchelt D.R., Slunt H.H., Ratovitsky T., Podlisny M., Selkoe D.J., Seeger M., Gandy S.E., Price D.L. (1996) Protein topology of presenilin 1. Neuron, 17, 1023–1030. [DOI] [PubMed] [Google Scholar]
- 4. Shen J., Bronson R.T., Chen D.F., Xia W., Selkoe D.J., Tonegawa S. (1997) Skeletal and CNS defects in presenilin-1-deficient mice. Cell, 89, 629–639. [DOI] [PubMed] [Google Scholar]
- 5. Wong P.C., Zheng H., Chen H., Becher M.W., Sirinathsinghji D.J., Trumbauer M.E., Chen H.Y., Price D.L., Van der Ploeg L.H., Sisodia S.S. (1997) Presenilin 1 is required for Notch1 and DII1 expression in the paraxial mesoderm. Nature, 387, 288–292. [DOI] [PubMed] [Google Scholar]
- 6. De Strooper B., Saftig P., Craessaerts K., Vanderstichele H., Guhde G., Annaert W., Von Figura K., Van Leuven F. (1998) Deficiency of presenilin-1 inhibits the normal cleavage of amyloid precursor protein. Nature, 391, 387–390. [DOI] [PubMed] [Google Scholar]
- 7. Struhl G., Greenwald I. (1999) Presenilin is required for activity and nuclear access of Notch in Drosophila. Nature, 398, 522–525. [DOI] [PubMed] [Google Scholar]
- 8. Ye Y., Lukinova N., Fortini M.E. (1999) Neurogenic phenotypes and altered Notch processing in Drosophila Presenilin mutants. Nature, 398, 525–529. [DOI] [PubMed] [Google Scholar]
- 9. Berridge M.J. (2011) Calcium signalling and Alzheimer’s disease. Neurochem. Res., 36, 1149–1156. [DOI] [PubMed] [Google Scholar]
- 10. Rajendran L., Annaert W. (2012) Membrane trafficking pathways in Alzheimer’s disease. Traffic, 13, 759–770. [DOI] [PubMed] [Google Scholar]
- 11. Georgakopoulos A., Marambaud P., Efthimiopoulos S., Shioi J., Cui W., Li H.C., Schutte M., Gordon R., Holstein G.R., Martinelli G. (1999) Presenilin-1 forms complexes with the cadherin/catenin cell-cell adhesion system and is recruited to intercellular and synaptic contacts. Mol. Cell, 4, 893–902. [DOI] [PubMed] [Google Scholar]
- 12. Donoviel D.B., Hadjantonakis A.K., Ikeda M., Zheng H., Hyslop P.S., Bernstein A. (1999) Mice lacking both presenilin genes exhibit early embryonic patterning defects. Genes Dev., 13, 2801–2810. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 13. Wolfe M.S., Xia W., Ostaszewski B.L., Diehl T.S., Kimberly W.T., Selkoe D.J. (1999) Two transmembrane aspartates in presenilin-1 required for presenilin endoproteolysis and gamma-secretase activity. Nature, 398, 513–517. [DOI] [PubMed] [Google Scholar]
- 14. Steiner H., Duff K., Capell A., Romig H., Grim M.G., Lincoln S., Hardy J., Yu X., Picciano M., Fechteler K.. et al. (1999) A loss of function mutation of presenilin-2 interferes with amyloid beta-peptide production and notch signaling. J. Biol. Chem., 274, 28669–28673. [DOI] [PubMed] [Google Scholar]
- 15. Rademakers R., Cruts M., Van Broeckhoven C. (2003) Genetics of early-onset Alzheimer dementia. ScientificWorldJournal, 3, 497–519. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 16. Lukinova N.I., Roussakova V.V., Fortini M.E. (1999) Genetic characterization of cytological region 77A-D harboring the presenilin gene of Drosophila melanogaster. Genetics, 153, 1789–1797. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 17. Marfany G., Del-Favero J., Valero R., De Jonghe C., Woodrow S., Hendriks L., Van Broeckhoven C., Gonzalez-Duarte R. (1998) Identification of a Drosophila presenilin homologue: evidence of alternatively spliced forms. J. Neurogenet., 12, 41–54. [DOI] [PubMed] [Google Scholar]
- 18. Ye Y., Fortini M.E. (1998) Characterization of Drosophila Presenilin and its colocalization with Notch during development. Mech. Dev., 79, 199–211. [DOI] [PubMed] [Google Scholar]
- 19. Thinakaran G., Borchelt D.R., Lee M.K., Slunt H.H., Spitzer L., Kim G., Ratovitsky T., Davenport F., Nordstedt C., Seeger M.. et al. (1996) Endoproteolysis of presenilin 1 and accumulation of processed derivatives in vivo. Neuron, 17, 181–190. [DOI] [PubMed] [Google Scholar]
- 20. Podlisny M.B., Citron M., Amarante P., Sherrington R., Xia W., Zhang J., Diehl T., Levesque G., Fraser P., Haass C.. et al. (1997) Presenilin proteins undergo heterogeneous endoproteolysis between Thr291 and Ala299 and occur as stable N- and C-terminal fragments in normal and Alzheimer brain tissue. Neurobiol. Dis., 3, 325–337. [DOI] [PubMed] [Google Scholar]
- 21. Campbell W.A., Reed M.L., Strahle J., Wolfe M.S., Xia W. (2003) Presenilin endoproteolysis mediated by an aspartyl protease activity pharmacologically distinct from gamma-secretase. J. Neurochem., 85, 1563–1574. [DOI] [PubMed] [Google Scholar]
- 22. Borchelt D.R., Thinakaran G., Eckman C.B., Lee M.K., Davenport F., Ratovitsky T., Prada C.M., Kim G., Seekins S., Yager D.. et al. (1996) Familial Alzheimer’s disease-linked presenilin 1 variants elevate Abeta1-42/1-40 ratio in vitro and in vivo. Neuron, 17, 1005–1013. [DOI] [PubMed] [Google Scholar]
- 23. Steiner H., Romig H., Grim M.G., Philipp U., Pesold B., Citron M., Baumeister R., Haass C. (1999) The biological and pathological function of the presenilin-1 Deltaexon 9 mutation is independent of its defect to undergo proteolytic processing. J. Biol. Chem., 274, 7615–7618. [DOI] [PubMed] [Google Scholar]
- 24. Knappenberger K.S., Tian G., Ye X., Sobotka-Briner C., Ghanekar S.V., Greenberg B.D., Scott C.W. (2004) Mechanism of gamma-secretase cleavage activation: is gamma-secretase regulated through autoinhibition involving the presenilin-1 exon 9 loop? Biochemistry, 43, 6208–6218. [DOI] [PubMed] [Google Scholar]
- 25. Li Y., Bohm C., Dodd R., Chen F., Qamar S., Schmitt-Ulms G., Fraser P.E., St George-Hyslop P.H. (2014) Structural biology of presenilin 1 complexes. Mol. Neurodegener., 9, 59.. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 26. Somavarapu A.K., Kepp K.P. (2016) The dynamic mechanism of presenilin-1 function: sensitive gate dynamics and loop unplugging control protein access. Neurobiol. Dis., 89, 147–156. [DOI] [PubMed] [Google Scholar]
- 27. Woodruff G., Young J.E., Martinez F.J., Buen F., Gore A., Kinaga J., Li Z., Yuan S.H., Zhang K., Goldstein L.S. (2013) The presenilin-1 DeltaE9 mutation results in reduced gamma-secretase activity, but not total loss of PS1 function, in isogenic human stem cells. Cell Rep., 5, 974–985. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 28. Saura C.A., Choi S.-Y., Beglopoulos V., Malkani S., Zhang D., Rao B.S.S., Chattarji S., Kelleher R.J., Kandel E.R., Duff K.. et al. (2004) Loss of presenilin function causes impairments of memory and synaptic plasticity followed by age-dependent neurodegeneration. Neuron, 42, 23–36. [DOI] [PubMed] [Google Scholar]
- 29. Kelleher R.J. III, Shen J. (2017) Presenilin-1 mutations and Alzheimer’s disease. Proc. Natl. Acad. Sci. U. S. A., 114, 629–631. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 30. Perez-Tur J., Froelich S., Prihar G., Crook R., Baker M., Duff K., Wragg M., Busfield F., Lendon C., Clark R.F. (1995) A mutation in Alzheimer’s disease destroying a splice acceptor site in the presenilin-1 gene. Neuroreport, 7, 297–301. [PubMed] [Google Scholar]
- 31. Lee M.K., Borchelt D.R., Kim G., Thinakaran G., Slunt H.H., Ratovitski T., Martin L.J., Kittur A., Gandy S., Levey A.I.. et al. (1997) Hyperaccumulation of FAD-linked presenilin 1 variants in vivo. Nat. Med., 3, 756–760. [DOI] [PubMed] [Google Scholar]
- 32. Kim S.H., Leem J.Y., Lah J.J., Slunt H.H., Levey A.I., Thinakaran G., Sisodia S.S. (2001) Multiple effects of aspartate mutant presenilin 1 on the processing and trafficking of amyloid precursor protein. J. Biol. Chem., 276, 43343–43350. [DOI] [PubMed] [Google Scholar]
- 33. Kimberly W.T., Xia W., Rahmati T., Wolfe M.S., Selkoe D.J. (2000) The transmembrane aspartates in presenilin 1 and 2 are obligatory for gamma-secretase activity and amyloid beta-protein generation. J. Biol. Chem., 275, 3173–3178. [DOI] [PubMed] [Google Scholar]
- 34. Ray W.J., Yao M., Mumm J., Schroeter E.H., Saftig P., Wolfe M., Selkoe D.J., Kopan R., Goate A.M. (1999) Cell surface presenilin-1 participates in the gamma-secretase-like proteolysis of Notch. J. Biol. Chem., 274, 36801–36807. [DOI] [PubMed] [Google Scholar]
- 35. Berezovska O., Jack C., McLean P., Aster J.C., Hicks C., Xia W., Wolfe M.S., Kimberly W.T., Weinmaster G., Selkoe D.J.. et al. (2002) Aspartate mutations in presenilin and gamma-secretase inhibitors both impair notch1 proteolysis and nuclear translocation with relative preservation of notch1 signaling. J. Neurochem., 75, 583–593. [DOI] [PubMed] [Google Scholar]
- 36. Steiner H., Haass C. (2000) Intramembrane proteolysis by presenilins. Nat. Rev. Mol. Cell Biol., 1, 217–224. [DOI] [PubMed] [Google Scholar]
- 37. Kang D.E., Soriano S., Xia X., Eberhart C.G., De Strooper B., Zheng H., Koo E.H. (2002) Presenilin couples the paired phosphorylation of beta-catenin independent of axin: implications for beta-catenin activation in tumorigenesis. Cell, 110, 751–762. [DOI] [PubMed] [Google Scholar]
- 38. Zhang Z., Hartmann H., Do V.M., Abramowski D., Sturchler-Pierrat C., Staufenbiel M., Sommer B., van de Wetering M., Clevers H., Saftig P.. et al. (1998) Destabilization of beta-catenin by mutations in presenilin-1 potentiates neuronal apoptosis. Nature, 395, 698–702. [DOI] [PubMed] [Google Scholar]
- 39. Kang D.E., Soriano S., Frosch M.P., Collins T., Naruse S., Sisodia S.S., Leibowitz G., Levine F., Koo E.H. (1999) Presenilin 1 facilitates the constitutive turnover of beta-catenin: differential activity of Alzheimer’s disease-linked PS1 mutants in the beta-catenin-signaling pathway. J. Neurosci., 19, 4229–4237. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 40. Murayama M., Tanaka S., Palacino J., Murayama O., Honda T., Sun X., Yasutake K., Nihonmatsu N., Wolozin B., Takashima A. (1998) Direct association of presenilin-1 with beta-catenin. FEBS Lett., 433, 73–77. [DOI] [PubMed] [Google Scholar]
- 41. Takashima A., Murayama M., Murayama O., Kohno T., Honda T., Yasutake K., Nihonmatsu N., Mercken M., Yamaguchi H., Sugihara S.. et al. (1998) Presenilin 1 associates with glycogen synthase kinase-3beta and its substrate tau. Proc. Natl. Acad. Sci. U. S. A., 95, 9637–9641. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 42. Gantier R., Gilbert D., Dumanchin C., Campion D., Davoust D., Toma F., Frebourg T. (2000) The pathogenic L392V mutation of presenilin 1 decreases the affinity to glycogen synthase kinase-3 beta. Neurosci. Lett., 283, 217–220. [DOI] [PubMed] [Google Scholar]
- 43. Prager K., Wang-Eckhardt L., Fluhrer R., Killick R., Barth E., Hampel H., Haass C., Walter J. (2007) A structural switch of presenilin 1 by glycogen synthase kinase 3beta-mediated phosphorylation regulates the interaction with beta-catenin and its nuclear signaling. J. Biol. Chem., 282, 14083–14093. [DOI] [PubMed] [Google Scholar]
- 44. Hiltunen M., Helisalmi S., Mannermaa A., Alafuzoff I., Koivisto A.M., Lehtovirta M., Pirskanen M., Sulkava R., Verkkoniemi A., Soininen H. (2000) Identification of a novel 4.6-kb genomic deletion in presenilin-1 gene which results in exclusion of exon 9 in a Finnish early onset Alzheimer’s disease family: an Alu core sequence-stimulated recombination? Eur. J. Hum. Genet., 8, 259–266. [DOI] [PubMed] [Google Scholar]
- 45. Kasa P., Papp H., Pakaski M. (2001) Presenilin-1 and its N-terminal and C-terminal fragments are transported in the sciatic nerve of rat. Brain Res., 909, 159–169. [DOI] [PubMed] [Google Scholar]
- 46. Papp H., Pakaski M., Kasa P. (2002) Presenilin-1 and the amyloid precursor protein are transported bidirectionally in the sciatic nerve of adult rat. Neurochem. Int., 41, 429–435. [DOI] [PubMed] [Google Scholar]
- 47. Sheng J.G., Price D.L., Koliatsos V.E. (2003) The beta-amyloid-related proteins presenilin 1 and BACE1 are axonally transported to nerve terminals in the brain. Exp. Neurol., 184, 1053–1057. [DOI] [PubMed] [Google Scholar]
- 48. Kamal A., Almenar-Queralt A., LeBlanc J.F., Roberts E.A., Goldstein L.S. (2001) Kinesin-mediated axonal transport of a membrane compartment containing beta-secretase and presenilin-1 requires APP. Nature, 414, 643–648. [DOI] [PubMed] [Google Scholar]
- 49. Gunawardena S., Yang G., Goldstein L.S. (2013) Presenilin controls kinesin-1 and dynein function during APP-vesicle transport in vivo. Hum. Mol. Genet., 22, 3828–3843. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 50. Weaver C., Leidel C., Szpankowski L., Farley N.M., Shubeita G.T., Goldstein L.S. (2013) Endogenous GSK-3/shaggy regulates bidirectional axonal transport of the amyloid precursor protein. Traffic, 14, 295–308. [DOI] [PubMed] [Google Scholar]
- 51. Dolma K., Iacobucci G.J., Hong Zheng K., Shandilya J., Toska E., White J.A. II, Spina E., Gunawardena S. (2014) Presenilin influences glycogen synthase kinase-3 beta (GSK-3beta) for kinesin-1 and dynein function during axonal transport. Hum. Mol. Genet., 23, 1121–1133. [DOI] [PubMed] [Google Scholar]
- 52. Gunawardena S., Goldstein L.S. (2001) Disruption of axonal transport and neuronal viability by amyloid precursor protein mutations in Drosophila. Neuron, 32, 389–401. [DOI] [PubMed] [Google Scholar]
- 53. Morfini G., Szebenyi G., Elluru R., Ratner N., Brady S.T. (2002) Glycogen synthase kinase 3 phosphorylates kinesin light chains and negatively regulates kinesin-based motility. EMBO J., 21, 281–293. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 54. Twomey C., McCarthy J.V. (2006) Presenilin-1 is an unprimed glycogen synthase kinase-3beta substrate. FEBS Lett., 580, 4015–4020. [DOI] [PubMed] [Google Scholar]
- 55. Uemura K., Kuzuya A., Shimozono Y., Aoyagi N., Ando K., Shimohama S., Kinoshita A. (2007) GSK3beta activity modifies the localization and function of presenilin 1. J. Biol. Chem., 282, 15823–15832. [DOI] [PubMed] [Google Scholar]
- 56. Gindhart J.G. Jr, Desai C.J., Beushausen S., Zinn K., Goldstein L.S. (1998) Kinesin light chains are essential for axonal transport in Drosophila. J. Cell Biol., 141, 443–454. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 57. Hurd D.D., Stern M., Saxton W.M. (1996) Mutation of the axonal transport motor kinesin enhances paralytic and suppresses Shaker in Drosophila. Genetics, 142, 195–204. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 58. Bowman A.B., Kamal A., Ritchings B.W., Philp A.V., McGrail M., Gindhart J.G., Goldstein L.S. (2000) Kinesin-dependent axonal transport is mediated by the sunday driver (SYD) protein. Cell, 103, 583–594. [DOI] [PubMed] [Google Scholar]
- 59. Falzone T.L., Gunawardena S., McCleary D., Reis G.F., Goldstein L.S. (2010) Kinesin-1 transport reductions enhance human tau hyperphosphorylation, aggregation and neurodegeneration in animal models of tauopathies. Hum. Mol. Genet., 19, 4399–4408. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 60. Gunawardena S., Her L.S., Brusch R.G., Laymon R.A., Niesman I.R., Gordesky-Gold B., Sintasath L., Bonini N.M., Goldstein L.S. (2003) Disruption of axonal transport by loss of huntingtin or expression of pathogenic polyQ proteins in Drosophila. Neuron, 40, 25–40. [DOI] [PubMed] [Google Scholar]
- 61. Haghnia M., Cavalli V., Shah S.B., Schimmelpfeng K., Brusch R., Yang G., Herrera C., Pilling A., Goldstein L.S. (2007) Dynactin is required for coordinated bidirectional motility, but not for dynein membrane attachment. Mol. Biol. Cell, 18, 2081–2089. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 62. Horiuchi D., Collins C.A., Bhat P., Barkus R.V., Diantonio A., Saxton W.M. (2007) Control of a kinesin-cargo linkage mechanism by JNK pathway kinases. Curr. Biol., 17, 1313–1317. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 63. Iacobucci G.J., Rahman N.A., Valtuena A.A., Nayak T.K., Gunawardena S. (2014) Spatial and temporal characteristics of normal and perturbed vesicle transport. PLoS One, 9, e97237.. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 64. Power D., Srinivasan S., Gunawardena S. (2012) In-vivo evidence for the disruption of Rab11 vesicle transport by loss of huntingtin. Neuroreport, 23, 970–977. [DOI] [PubMed] [Google Scholar]
- 65. White J.A., Anderson E., Zimmerman K., Zheng K.H., Rouhani R., Gunawardena S. (2015) Huntingtin differentially regulates the axonal transport of a sub-set of Rab-containing vesicles in vivo. Hum. Mol. Genet., 24, 7182–7195. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 66. Duncan J.E., Lytle N.K., Zuniga A., Goldstein L.S. (2013) The microtubule regulatory protein stathmin is required to maintain the integrity of axonal microtubules in Drosophila. PLoS One, 8, e68324.. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 67. Sisodia S.S., Kim S.H., Thinakaran G. (1999) Function and dysfunction of the presenilins. Am. J. Hum. Genet., 65, 7–12. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 68. Noll E., Medina M., Hartley D., Zhou J., Perrimon N., Kosik K.S. (2000) Presenilin affects arm/beta-catenin localization and function in Drosophila. Dev. Biol., 227, 450–464. [DOI] [PubMed] [Google Scholar]
- 69. Lee K.D., Hollenbeck P.J. (1995) Phosphorylation of kinesin in vivo correlates with organelle association and neurite outgrowth. J. Biol. Chem., 270, 5600–5605. [DOI] [PubMed] [Google Scholar]
- 70. Gao F.J., Hebbar S., Gao X.A., Alexander M., Pandey J.P., Walla M.D., Cotham W.E., King S.J., Smith D.S. (2015) GSK-3beta phosphorylation of cytoplasmic dynein reduces Ndel1 binding to intermediate chains and alters dynein motility. Traffic, 16, 941–961. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 71. McIlvain J.M. Jr, Burkhardt J.K., Hamm-Alvarez S., Argon Y., Sheetz M.P. (1994) Regulation of kinesin activity by phosphorylation of kinesin-associated proteins. J. Biol. Chem., 269, 19176–19182. [PubMed] [Google Scholar]
- 72. Annaert W.G., Levesque L., Craessaerts K., Dierinck I., Snellings G., Westaway D., George-Hyslop P.S., Cordell B., Fraser P., De Strooper B. (1999) Presenilin 1 controls gamma-secretase processing of amyloid precursor protein in pre-golgi compartments of hippocampal neurons. J. Cell Biol., 147, 277–294. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 73. Chyung J.H., Raper D.M., Selkoe D.J. (2005) Gamma-secretase exists on the plasma membrane as an intact complex that accepts substrates and effects intramembrane cleavage. J. Biol. Chem., 280, 4383–4392. [DOI] [PubMed] [Google Scholar]
- 74. Bourouis M. (2002) Targeted increase in shaggy activity levels blockages wingless signaling. Genesis, 34, 99–102. [DOI] [PubMed] [Google Scholar]
- 75. Kirschenbaum F., Hsu S.C., Cordell B., McCarthy J.V. (2001) Substitution of a glycogen synthase kinase-3beta phosphorylation site in presenilin 1 separates presenilin function from beta-catenin signaling. J. Biol. Chem., 276, 7366–7375. [DOI] [PubMed] [Google Scholar]
- 76. McCarthy J.V. (2005) Involvement of presenilins in cell-survival signalling pathways. Biochem. Soc. Trans., 33, 568–572. [DOI] [PubMed] [Google Scholar]
- 77. Saura C.A., Tomita T., Soriano S., Takahashi M., Leem J.Y., Honda T., Koo E.H., Iwatsubo T., Thinakaran G. (2000) The nonconserved hydrophilic loop domain of presenilin (PS) is not required for PS endoproteolysis or enhanced abeta 42 production mediated by familial early onset Alzheimer’s disease-linked PS variants. J. Biol. Chem., 275, 17136–17142. [DOI] [PubMed] [Google Scholar]
- 78. Maesako M., Horlacher J., Zoltowska K.M., Kastanenka K.V., Kara E., Svirsky S., Keller L.J., Li X., Hyman B.T., Bacskai B.J., Berezovska O. (2017) Pathogenic PS1 phosphorylation at Ser367. Elife, 6. Doi: 10.7554/eLife.19720. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 79. Wahlster L., Arimon M., Nasser-Ghodsi N., Post K.L., Serrano-Pozo A., Uemura K., Berezovska O. (2013) Presenilin-1 adopts pathogenic conformation in normal aging and in sporadic Alzheimer’s disease. Acta Neuropathol., 125, 187–199. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 80. Gudkov A.V., Kazarov A.R., Thimmapaya R., Axenovich S.A., Mazo I.A., Roninson I.B. (1994) Cloning mammalian genes by expression selection of genetic suppressor elements: association of kinesin with drug resistance and cell immortalization. Proc. Natl. Acad. Sci. U. S. A., 91, 3744–3748. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 81. Niclas J., Navone F., Hom-Booker N., Vale R.D. (1994) Cloning and localization of a conventional kinesin motor expressed exclusively in neurons. Neuron, 12, 1059–1072. [DOI] [PubMed] [Google Scholar]
- 82. Nakagawa T., Tanaka Y., Matsuoka E., Kondo S., Okada Y., Noda Y., Kanai Y., Hirokawa N. (1997) Identification and classification of 16 new kinesin superfamily (KIF) proteins in mouse genome. Proc. Natl. Acad. Sci. U. S. A., 94, 9654–9659. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 83. Xia C., Rahman A., Yang Z., Goldstein L.S. (1998) Chromosomal localization reveals three kinesin heavy chain genes in mouse. Genomics, 52, 209–213. [DOI] [PubMed] [Google Scholar]
- 84. McDonald A., Fogarty S., Leclerc I., Hill E.V., Hardie D.G., Rutter G.A. (2010) Cell-wide analysis of secretory granule dynamics in three dimensions in living pancreatic beta-cells: evidence against a role for AMPK-dependent phosphorylation of KLC1 at Ser517/Ser520 in glucose-stimulated insulin granule movement. Biochem. Soc. Trans., 38, 205–208. [DOI] [PubMed] [Google Scholar]
- 85. Hollenbeck P.J. (1993) Phosphorylation of neuronal kinesin heavy and light chains in vivo. J. Neurochem., 60, 2265–2275. [DOI] [PubMed] [Google Scholar]
- 86. Schafer B., Gotz C., Dudek J., Hessenauer A., Matti U., Montenarh M. (2009) KIF5C: a new binding partner for protein kinase CK2 with a preference for the CK2alpha’ subunit. Cell. Mol. Life Sci., 66, 339–349. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 87. Verhey K.J., Hammond J.W. (2009) Traffic control: regulation of kinesin motors. Nat. Rev. Mol. Cell Biol., 10, 765–777. [DOI] [PubMed] [Google Scholar]
- 88. Woźniak M.J., Allan V.J. (2006) Cargo selection by specific kinesin light chain 1 isoforms. EMBO J., 25, 5457–5468. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 89. Verhey K.J., Meyer D., Deehan R., Blenis J., Schnapp B.J., Rapoport T.A., Margolis B. (2001) Cargo of kinesin identified as JIP scaffolding proteins and associated signaling molecules. J. Cell Biol., 152, 959–970. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 90. Pigino G., Morfini G., Pelsman A., Mattson M.P., Brady S.T., Busciglio J. (2003) Alzheimer’s presenilin 1 mutations impair kinesin-based axonal transport. J. Neurosci., 23, 4499–4508. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 91. Stokin G.B., Almenar-Queralt A., Gunawardena S., Rodrigues E.M., Falzone T., Kim J., Lillo C., Mount S.L., Roberts E.A., McGowan E., Williams D.S., Goldstein L.S.B. (2008) Amyloid precursor protein-induced axonopathies are independent of amyloid-beta peptides. Hum. Mol. Genet., 17, 3474–3486. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 92. Fye S., Dolma K., Kang M.J., Gunawardena S. (2010) Visualization of larval segmental nerves in 3(rd) instar Drosophila larval preparations. J. Vis. Exp., in press. 43, pii: 2128. Doi: 10.3791/2128. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 93. Day R.W., Quinn G.P. (1989) Comparisons of treatments after an analysis of variance in ecology. Ecol. Monogr., 59, 433–463. [Google Scholar]
- 94. Stewart-Oaten A. (1995) Rules and judgements in statistics: three examples. Ecology, 76, 2001–2009. [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.